Nanoform announces biological nanoparticle-forming technology

Nanoform Finland Plc. (Nanoform; Helsinki, Finland) has announced its launch of a proprietary, early-development technology that can form biological nanoparticles as small as 50nm. In the same press release, the company also announced its setting of a new 2021 near-term business target, relating to its delivery of its first biologics proof-of-concept project for the newly launched technology with a pharmaceutical or biotech industry partner. The increasing complexity of drug molecules means that drug delivery methods may also become more complex. The hope is that new technologies, such as Nanoform’s nanoparticle-forming technology, could help improve factors including drug delivery route and...